Project Oncology®

ReachMD

Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer. Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.

  1. May 15

    Addressing Barriers to CAR T Referral in R/R LBCL

    Host: Steve Jackson, PharmD Guest: Matthew J. Matasar, MD Guest: Tycel Phillips, MD This is a non-certified educational series produced and controlled by ReachMD. Timely referral for CAR T-cell therapy remains a critical challenge for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). From communication gaps between providers to logistical challenges and delays, barriers throughout the treatment pathway can limit timely access to care. Tune in to learn about evolving strategies that can help us streamline coordination and expand access to CAR T-cell therapy as Dr. Steve Jackson speaks with Dr. Matthew Matasar and Dr. Tycel Phillips. Dr. Matasar is the Chief of Blood Disorders at Rutgers Cancer Institute and a Professor of Medicine at Rutgers Robert Wood Johnson Medical School in New Brunswick, New Jersey. Dr. Phillips is an Associate Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope in Duarte, California.

    13 min

  2. May 15

    ReDiscover-2: Currently Enrolling Patients With PIK3CA-Mutated Advanced Breast Cancer

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Sammons, MD Despite advances in the treatment of HR-positive HER2-negative advanced breast cancer, patients with PIK3CA-mutated disease who progress after a CDK4/6 inhibitor still face limited effective and tolerable treatment options.1 This unmet need has fueled interest in zovegalisib (formerly RLY-2608), a next generation, pan-mutant-selective PI3Kα inhibitor designed to spare wild-type protein and potentially reduce class-related toxicities.2 Dr. Sarah Sammons joins Dr. Charles Turck to review key findings from the first-in-human ReDiscover trial of zovegalisib + fulvestrant that supported initiation of the Phase 3 ReDiscover-2 study3,4, which is currently enrolling. They also discuss ReDiscover-2 eligibility criteria, along with patient selection and screening considerations, using hypothetical case scenarios. Dr. Sammons is the Associate Director of the Metastatic Breast Cancer Program at the Dana-Farber Cancer Institute in Boston, Massachusetts. References: Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7)doi:10.3390/ijms22073464 Varkaris A, Pazolli E, Gunaydin H, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Kα inhibitor that decouples antitumor activity from hyperinsulinemia. Cancer Discovery. 2024;14(2):240–257. doi:10.1158/2159-8290.cd-23-0944 ClinicalTrials.gov. NCT06982521. Accessed April 12, 2026. https://clinicaltrials.gov/study/NCT06982521 Rugo HS, Saura C, Jhaveri K, et al. Poster PS5-08-25: …

    17 min

  3. May 8

    Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Petros Grivas, MD, PhD Could emerging biomarkers redefine how we assess response and recurrence risk in muscle-invasive bladder cancer? To find out, Dr. Charles Turck speaks with Dr. Petros Grivas about the key findings from the phase 3 NIAGARA trial. Together, they explore how perioperative durvalumab impacts circulating tumor DNA (ctDNA) clearance and clinical outcomes, including event-free and overall survival. Their conversation also highlights the prognostic value of ctDNA and the potential for urinary tumor DNA to more closely correlate with pathologic complete response. Dr. Grivas is a Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine, as well as the Clinical Research Division at the Fred Hutchinson Cancer Center, where he's also the Medical Director of the International Program and of local and regional outreach.

    14 min

  4. Apr 30

    ctDNA-Guided Adjuvant Atezolizumab in MIBC: IMvigor011 Insights

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Guru P. Sonpavde, MD What if molecular relapse in muscle-invasive bladder cancer (MIBC) could be detected early enough to better inform treatment decisions? To find out, Dr. Charles Turck speaks with Dr. Guru Sonpavde to explore new IMvigor011 findings presented at the 2026 ASCO Genitourinary Cancers Symposium. Their discussion highlights how ctDNA monitoring identifies early recurrence risk, captures real-time immunotherapy activity, and positions ctDNA clearance as a powerful prognostic marker. Dr. Sonpavde is the Medical Director of Genitourinary Oncology and the Phase I Clinical Research Unit, and the Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute in Orlando.

    9 min

  5. Apr 9

    ctDNA-Guided Bladder Preservation in Muscle-Invasive Bladder Cancer

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Pooja Ghatalia, MD Emerging evidence is redefining bladder preservation strategies in muscle-invasive bladder cancer, with circulating tumor DNA (ctDNA) offering a novel approach to response-adapted care. Joining Dr. Charles Turck to review findings from the phase II RETAIN trials, which highlight how ctDNA clearance correlates with improved metastasis-free survival and informs risk stratification, is Dr. Pooja Ghatalia. She also examines the strengths and limitations of ctDNA, including its prognostic value for systemic recurrence and its inability to reliably detect localized disease. Dr. Ghatalia is an Associate Professor in the Department of Hematology and Oncology at Fox Chase Cancer Center at Temple University Hospital in Philadelphia, and she presented this research at the 2026 ASCO Genitourinary Cancers Symposium.

    11 min

  6. Feb 13

    Expanding Access to CAR T-Cell Therapy in R/R Myeloma Care

    Host: Brian P. McDonough, MD, FAAFP Guest: Tara Graff, DO, MS Guest: Surbhi Sidana, MD This is a non-certified educational series produced and controlled by ReachMD. While BCMA-directed CAR T-cell therapy has changed the treatment landscape for patients with relapsed and refractory (R/R) multiple myeloma, access remains uneven outside academic centers. In this expert-led discussion, Dr. Brian McDonough, Dr. Surbhi Sidana, and Dr. Tara Graff explore real-world barriers to referral and delivery, evolving care models, and the multidisciplinary coordination required to extend CAR T therapy into community practice. Dr. Sidana is an Associate Professor of Medicine, and she leads the Myeloma CAR T and Immunotherapy program at Stanford Medicine. Dr. Graff is the Director of Clinical Research at Mission Cancer + Blood, and she serves on the National CAR T-Cell Advisory Board for Multiple Myeloma.

    14 min

  7. Feb 12

    Tracking Treatment Response: ctDNA Insights in MMR-p Colon Cancer

    Host: Brian P. McDonough, MD, FAAFP Guest: Christopher T. Chen, MD What if a simple blood draw could reveal whether a patient is responding to treatment before surgery? That question is at the heart of a study presented at the 2025 ESMO Congress, which investigated neoadjuvant immune checkpoint blockade in mismatch-repair-proficient (MMR-p) colon cancer. In addition to confirming that combination immunotherapy prior to surgery is a safe and feasible approach, the study also found that circulating tumor DNA (ctDNA) levels correlated with both tumor burden and early treatment response. Joining Dr. Brian McDonough to unpack these insights is Dr. Christopher Chen, Assistant Professor in the Division of Oncology in the Department of Medicine at Stanford University School of Medicine.

    9 min

  8. Jan 30

    How the 2025 IMWG Guidelines are Reshaping Sequencing in R/R Multiple Myeloma

    Host: Jennifer Caudle, DO, FACOFP Guest: Mansi R. Shah, MD This is a non-certified educational series produced and controlled by ReachMD. The latest International Myeloma Working Group (IMWG) guidelines emphasize immune function, relapse timing, and therapeutic intent to guide the sequencing of T-cell-redirecting therapies in relapsed/refractory (R/R) multiple myeloma. Hear key updates as Dr. Jennifer Caudle and Dr. Mansi Shah discuss how we can integrate T-cell redirecting therapies into patient care more intentionally. Dr. Shah is an Associate Professor and the Clinical Director of Multiple Myeloma at the Rutgers Cancer Institute.

    14 min
See All (179)

Ratings & Reviews

4.5
out of 5
2 Ratings

About

Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer. Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.

Information

  • Creator
    ReachMD
  • Years Active
    2017 - 2026
  • Episodes
    179
  • Rating
    Clean
  • Copyright
    © Copyright 2026 ReachMD. All rights reserved.
  • Show Website
    Project Oncology®

You Might Also Like